BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BioCentury | Mar 10, 2017
Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
BioCentury | Jun 23, 2016
Distillery Techniques

Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate

Drug platforms TECHNOLOGY: Structural analyses Structural analyses of PRC2 bound to an inhibitor or histone H3 substrate could help guide the development of PRC2 inhibitors for cancer that bypass known mechanisms of resistance. Analysis of...
BioCentury | Feb 18, 2016
Distillery Techniques

Techniques: Lysine demethylase 5D (KDM5D; JARID1D) as a survival marker in prostate cancer

Biomarkers TECHNOLOGY: Gene profiling Tumor levels of KDM5D could help predict survival in prostate cancer. In 39 prostate cancer patients, low levels of KDM5D in primary tumors were associated with poor survival. Next steps could...
BioCentury | Aug 15, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Jumonji/ARID domain containing protein 1C (KDM5C; JARID1C) Studies in patient samples, cultured cells and flies suggest inhibiting JARID1C could help to treat...
BioCentury | Jul 25, 2013
Distillery Therapeutics

Indication: Cancer

...could help treat drug-resistant melanoma. In cultured, drug-resistant melanoma cells that highly expressed jumonji AT rich interactive domain 1B (JARID1B; PLU-1...
...set of compounds alone. Next steps include understanding the basis for mitochondria-mediated drug resistance in JARID1B-overexpressing...
BioCentury | Oct 4, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Not applicable A study in rats suggests neural stem cell transplantation could help treat SCI. In rats with transected spinal cords,...
BioCentury | Jun 9, 2008
Emerging Company Profile

Constellation: More epigenetic stars

...paper in Molecular Cell that showed Jumonji, AT rich interactive domain 1B ( JARID1B , PLU-1...
Items per page:
1 - 8 of 8